A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 4, 2011, Pages 711-718

  Morota, Kaori ^a   Nakagawa, Masatoshi ^a   Sekiya, Rika ^a   Hemken, Philip M ^b   Sokoll, Lori J ^c   Elliott, Debra ^c   Chan, Daniel W ^c   Dowell, Barry L ^b  

^a Abbott Japan Co Ltd   (Japan)

^b ABBOTT LABORATORIES   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cirrhosis; fucosylation; Golgi protein 73; hepatocellular carcinoma; liver disease

Indexed keywords

ALPHA FETOPROTEIN; CELL PROTEIN; DECARBOXYPROTHROMBIN; GOLGI PROTEIN 73; HEMOPEXIN; LECTIN; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ALEURIA AURANTIA; AREA UNDER THE CURVE; ARTICLE; ASCOMYCETES; CHEMOLUMINESCENCE; CHRONIC HEPATITIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FUCOSYLATION; GOLGI COMPLEX; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ALPHA-FETOPROTEINS; ANIMALS; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; CARCINOMA, HEPATOCELLULAR; CHEMILUMINESCENT MEASUREMENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HEMOPEXIN; HEPATITIS, CHRONIC; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; PROTEIN PRECURSORS; PROTHROMBIN; REFERENCE STANDARDS; ROC CURVE;

ALEURIA AURANTIA; ORYCTOLAGUS CUNICULUS;

EID: 79954490259     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.097     Document Type: Article

References (27)

1. Jelic S. Hepatocellular carcinoma: ESMO clinical recommenda-tions for diagnosis, treatment and follow-up. Ann Oncol 2009; 20:41-5.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127 (Suppl):5-16.
3. El-Serag HB. Epidemiology of hepatocellular carcinomain USA. Hepatol Res 2007;37(Suppl):88-94.
4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular car-cinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(Suppl):35- 50.
5. Makuuchi A, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawa-saki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37-51. (Pubitemid 350182575)
6. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-7-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-9. (Pubitemid 32105702)
7. Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, et al. Prognostic significance ofanatomical resec-tion and des-7-carboxy prothrombin in patients with hepato-cellular carcinoma. Br J Surg 1999;86:1032-8. (Pubitemid 29387069)
8. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and manage-ment of patients with hepatocellular carcinoma. Oncology 2002;62(Suppl):57-63. (Pubitemid 34702021)
9. Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, et al. GP73, a novel Golgi-localized protein upreg-ulated by viral infection. Gene 2000;249:53-65. (Pubitemid 30300752)
10. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fim-mel CJ, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005;43: 1007-12. (Pubitemid 41627986)
11. Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pes-talozzi BC, et al. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology 2009;49:1602-9.
12. Gu Y, Chen W, Zhao Y, Chen L, Peng T Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver disease. Ann Clin Biochem 2009;46:38-43.
13. Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, Asakura H. The fucosylation index of α-fetoprotein as a possible prog-nostic indicator for patients with hepatocellular carcinoma. Cancer 1998;83:2076-82. (Pubitemid 28525388)
14. Okuda K, Tanaka M, Kanazawa N, Nagashima J, Satomura S, Kinoshita H, et al. Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein. Int J Oncol 1999;14:265-71.
15. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Bisceglie AM, et al. Novel fucosylated biomarkers forthe early detection of hepatocellular carcinoma. Cancer Epidem Biomar 2009;18:1914-21.
16. Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, et al. Proteomic analysis of serum associated fuco-sylated glycoproteins in the development of primary hepato-cellular carcinoma. J Proteome Res 2006;5:308-15. (Pubitemid 43224256)
17. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in wood-chucks and humans. Proc Natl Acad Sci USA 2005;102: 779-84. (Pubitemid 40282742)
18. Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A, et al. Lectin capture strategies combined with mass spectro-metry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics 2006;5:1957-67. (Pubitemid 44688203)
19. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80. (Pubitemid 24049800)
20. Tolosano E, Altruda F. Hemopexin: structure, function, and reg-ulation. DNA Cell Biol 2002;21:297-306.
21. Jia W, Lu Z, Wang H, Wang L, Chi H, Yuan Z, et al. Strategy for precise and large scale identification of core fucosylated glycoproteins. Mol Cell Proteomics 2009;8:913-23.
22. Wimmerova M, Mitchell E, Sanchez JF, Gautier C, Imberty A. Crystal structure of fungal lectin: six-bladed ß-propeller fold and novel fucose recognition mode for Aleuria aurantia lectin. J Biol Chem 2003;278:27059-67. (Pubitemid 36876860)
23. Perkins NJ, Schisterman EF. The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver oper-ating characteristics curve. Am J Epidemiol 2006;163:670-5.
24. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-7-carboxy prothrombin and α-feto-protein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010;138:493-502.
25. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Rob-erts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrom-bin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:26-9.
26. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expres-sion of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 2002;35:1431-40. (Pubitemid 34966897)
27. Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Gräff A, Gus-mirovic I, Solomon H, et al. Disease-and cell-specific expres-sion of GP73 in human liver disease. Am J Gastroenterol 2004; 99:1087-95. (Pubitemid 38917813)